236 related articles for article (PubMed ID: 37505794)
1. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Castellino SM; Giulino-Roth L; Harker-Murray P; Kahn JM; Forlenza C; Cho S; Hoppe B; Parsons SK; Kelly KM;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30580. PubMed ID: 37505794
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
5. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
8. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
9. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
11. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
12. New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond.
Caro J; Diefenbach C
Expert Rev Hematol; 2021 Aug; 14(8):741-750. PubMed ID: 34350815
[No Abstract] [Full Text] [Related]
13. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
19. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
Plattel WJ; Bergamasco A; Trinchese F; Gavini F; Bent-Ennakhil N; Zomas A; Castillon G; Arredondo-Bisono T; Cristarella T; Moride Y; von Tresckow B
Leuk Lymphoma; 2021 Dec; 62(14):3320-3332. PubMed ID: 34323643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
